Navigation Links
Roche Symposium Showcases Accomplishments of Next Generation of Chemists

NUTLEY, N.J., May 23, 2011 /PRNewswire/ -- Today, Roche honored 12 outstanding PhD students and two professors with the company's Excellence in Chemistry Award for research accomplishments in the field of organic chemistry. The winners are participating in Roche's annual two-day Roche Symposium: Excellence in Chemistry to gain first hand knowledge on the important role organic chemistry plays in pharmaceutical discovery.

"These students come from a broad range of universities and experiences and are some of the best and brightest in the field," said Karen Lackey, Vice President and Head, Discovery Chemistry at Roche. "We welcome their insights and expertise as well as the opportunity to showcase how chemistry plays a vital role in the development of new medicines."

During the symposium, students will have opportunities to discuss their research projects, hear overviews of the drug discovery process by Roche scientists, and case histories in medicinal and process chemistry as well as tour the Nutley campus. There will also be a plenary lecture by the 2011 faculty award winner Professor Vy Dong of the University of Toronto in Canada.  Professor David Gin of the Sloan-Kettering Cancer Center, who passed away in March of 2011, was also selected as one of this year's plenary lecturers. In his honor, Troy Reynolds of Memorial Sloan-Kettering Cancer Center is a guest speaker.

2011 Student Recipients
Representing a range of 10 prestigious institutions, the 12 winners this year are: D. Karl Bedke (University of California, Irvine), Ian Dailey (University of Illinois at Urbana-Champaign), Adel ElSohly (Columbia University), Fang Gao (Boston College), Allen Hong (California Institute of Technology), Daniel Robbins (University of Illinois at Urbana-Champaign), David Sarlah (The Scripps Research Institute), Danielle Schultz (University of Michigan), Jun Shi (The Scripps Research Institute), Genessa Smith (Colorado State University), Andy Tsai (Yale University), and Zhan Wang (University of California, Berkeley).

Selection Process
Students were nominated by their faculty advisors and selected by a committee comprised of Roche scientists. Eligible students were advanced graduate students who might be interested in the pharmaceutical industry as a career. Besides the opportunity to attend and present their research projects at the symposium, the students each received a crystal award and an honorarium. Professor Dong received an unrestricted grant to support her ongoing research in addition to the honorarium and a research grant in honor of the late Professor Gin is being awarded to Memorial Sloan-Kettering Cancer Center.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

All trademarks used or mentioned in this release are protected by law.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):